Topic: Drug Pricing

  • Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

    Medicare Negotiation: A “Too Little” or “Too Late” Framework for Drug Selection

  • Fact Check: Time to Market for New Drugs in U.S. Versus Other Countries

  • Abandon Biosimilars as Biologics are Natural Monopolies

  • Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

    Impact of President’s Budget and Point of Sale Rebate Proposal for Part D: 10 Year Projection

  • The “Netflix Model” of Financing Hepatitis C Treatment

    The “Netflix Model” of Financing Hepatitis C Treatment

  • Cardiovascular Drugs Not Price Aligned with Value in US

  • Spending On Prescription Drugs In The US: Where Does All The Money Go?

    Spending On Prescription Drugs In The US: Where Does All The Money Go?

  • DPL responds to HHS Blueprint (May 16, 2018)

  • Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold

    Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold

  • Outcomes-Based Drug Contracts Do Not Move Us Closer to Value

    Outcomes-Based Drug Contracts Do Not Move Us Closer to Value